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ABSTRACT
Mutation of the essential yeast protein Ipa1 has previously been demonstrated to cause defects in pre-
mRNA 3ʹ end processing and growth, but the mechanism underlying these defects was not clear. In this
study, we show that the ipa1-1 mutation causes a striking depletion of Ysh1, the evolutionarily
conserved endonuclease subunit of the 19-subunit mRNA Cleavage/Polyadenylation (C/P) complex,
but does not decrease other C/P subunits. YSH1 overexpression rescues both the growth and 3ʹ end
processing defects of the ipa1-1 mutant. YSH1 mRNA level is unchanged in ipa1-1 cells, and proteasome
inactivation prevents Ysh1 loss and causes accumulation of ubiquitinated Ysh1. Ysh1 ubiquitination is
mediated by the Ubc4 ubiquitin-conjugating enzyme and Mpe1, which in addition to its function in C/P,
is also a RING ubiquitin ligase. In summary, Ipa1 affects mRNA processing by controlling the availability
of the C/P endonuclease and may represent a regulatory mechanism that could be rapidly deployed to
facilitate reprogramming of cellular responses.
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Tight regulation of gene expression is critical for proper
cellular function. A step of mRNA synthesis that can influence
gene expression is mRNA polyadenylation, an essential
maturation step in which mRNA precursor is trimmed by
cleavage at its 3ʹ end and a poly(A) tail added. Regulating
the overall efficiency at which this processing occurs is
a mechanism by which cells could globally alter the amount
of mRNAs that reach the cytoplasm for translation. In
a different regulatory strategy, a process known as alternative
polyadenylation results in a change in the cleavage site posi-
tion to yield specific mRNA isoforms with different lengths of
3ʹ untranslated (3ʹ UTRs) or coding regions. Shortening of the
3ʹ UTR removes binding sites for factors that influence
mRNA stability, translation, subcellular localization, and part-
ner protein interaction, while coding region shortening alters
protein function [1,2]. Alternative polyadenylation plays an
important and increasingly appreciated role in regulation of
gene expression, and the choice of poly(A) site has been
shown to vary with changes in cell state during development,
tissue differentiation, tumorigenesis, senescence, and as part
of the response to stress or infection [3–17].
Regulation of polyadenylation can be elicited by changing
the relative concentration of the core mRNA 3ʹ end proces-
sing factors or their recruitment to RNA Polymerase II (Pol
II) elongation complexes, by affecting how quickly Pol II
reaches downstream poly(A) sites, and in some cases, by the
expression of positive or negative regulators [7,10,12,18].
Post-translational modification of processing factors is
another mechanism for regulation of mRNA 3ʹ end forma-
tion. Modifications such as phosphorylation [19–26], acetyla-
tion [27], and sumoylation [28] have all been reported to
affect the activity of the Cleavage/Polyadenylation (C/P) com-
plex or usage of alternative poly(A) sites. Many studies have
also shown that experimental depletion of subunits of the C/P
complex can lead to changes in the choice of poly(A) sites
(reviewed in [7] and [12]).
In yeast, the C/P complex is composed of CPF, CF IA, and
CF IB. CPF contains 14 subunits and includes the enzymes of
the complex, which are the Ysh1 endonuclease, the Pap1
poly(A) polymerase, and two phosphatases, Ssu72 and Glc7,
which can act on RNA Polymerase II (Pol II). CF IA, which
has four subunits (Clp1, Pcf11, Rna14 and Rna15), provides
RNA recognition and scaffolding functions to bring together
CPF, CF IB, and Pol II. CF IB is the RNA-binding protein
Hrp1. The C/P machinery is highly conserved from yeast to
mammals [10,29,30], and proteins with sequence, functional,
and/or structural homology to almost all of the yeast subunits
can be found in the mammalian C/P complex.
While much progress has been made recently to elucidate
the composition of the C/P complex and its structural orga-
nization [29,30], regulatory mechanisms that lead to changes
in levels of C/P subunits are not so well defined. One mechan-
ism that has been described is regulation of the amount of the
CF IA subunits Pcf11 and Rna14 and their metazoan homo-
logs PCF11 and CSTF3 by premature transcription
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termination upstream of the gene’s stop codon [31]. In addi-
tion, alterations in the expression of mRNAs encoding C/P
subunits have been reported upon cell differentiation,
increased proliferation, or in response to external stimuli
[32], but these changes do not always correlate with changes
in protein levels [5,33].
The levels of C/P proteins could also be regulated by
changes in translation or protein stability. We have previously
shown that ubiquitination, a modification that can lead to
protein degradation, can modulate C/P efficiency, but mole-
cular targets were not identified [34]. An attractive target for
this type of regulation would be the endonuclease (Ysh1 in
yeast and CPSF73 in mammals) [35]. The activity of this
enzyme initiates mRNA 3ʹ end processing, and if it is
depleted, 3ʹ ends are not generated for poly(A) addition, and
Pol II transcription does not terminate efficiently [36–38].
In this study, we describe how the level of Ysh1 is regulated by
ubiquitin-mediated proteasomal degradation. This targeting of
Ysh1 is modulated by the presence of Ipa1, an essential protein
that was initially discovered as a factor whose genetic interaction
profile was very similar to those of mRNA 3ʹ end processing
factors [39]. Ipa1 forms a stable complex with only the Ysh1 and
Mpe1 subunits of the C/P complex [39,40]. We have previously
shown that the ipa1-1 mutant allele causes a defect in both the
cleavage and poly(A) addition steps of mRNA 3ʹ end processing
in vitro, lengthening of mRNAs in vivo, inefficient transcription
termination downstream of poly(A) sites and at snoRNA genes,
and poor recruitment of the Pta1 subunit of the C/P complex to
the 3ʹ end of an mRNA gene [39,41]. We now show that Ipa1
exerts its effects on mRNA 3ʹ end processing by blocking the
ubiquitination of Ysh1, a regulatory mechanism that has not
previously been reported.
Results
Ysh1 protein level is decreased by Ipa1 mutation
Because the ipa1-1 phenotypes were reminiscent of those of 3ʹ-
end processing mutants, we investigated whether the levels of
subunits of the C/P complex were altered in ipa1-1. Western
blot analysis of whole-cell extract of ipa1-1 showed most sub-
units were not affected. However, some subunits (Rna14, Clp1,
Cft1, and Swd2) were increased in level (Fig. 1A), while Ysh1
was the only subunit that showed a striking decrease. Thus, the
ipa1-1 mutation alters the stoichiometry of C/P complex sub-
units in ways that could explain the processing defects.
Recent findings indicate that CPF can be sub-divided into
three enzymatic modules: a nuclease module, a phosphatase
module (also called APT for Associated with Pta1), and
a polymerase module [40,42,43]. To test whether the CPF
organization is compromised in ipa1-1, we performed a co-
immunoprecipitation experiment using wild-type or ipa1-1
extracts and antibody against Pap1. The composition of
immunoprecipitated proteins was assessed by Western blot-
ting with antibodies against subunits of CPF and CF IA.
Consistent with the low level of Ysh1 in ipa1-1 extract, less
Ysh1 was incorporated into CPF (Fig. 1B). Mpe1, Pta1, and
Ssu72 also showed decreased incorporation into CPF despite
normal levels in the ipa1-1 total extract (Fig. 1B). The loss of
these subunits is likely due to low Ysh1 incorporation into
CPF as Ysh1 directly interacts with Mpe1 and Pta1, and Pta1
in turn recruits Ssu72 to the processing machinery [42,44,45].
This result supports the proposal of Casanal, et al. [42] that
the nuclease module functions as a bridge to connect the
polymerase and phosphatase modules. The interactions of
Pap1 with Pfs2 and Fip1 were not affected, as would be
expected given that Fip1 directly contacts both Pap1 and
Pfs2 [46,47]. Furthermore, the cross-factor interaction
between CPF and the CF IA subunits Rna14 and Rna15 was
not impaired by the ipa1-1 mutation. Consistent with defects
in CPF composition in ipa1-1, defects in cleavage and poly(A)
addition seen with in vitro reactions using the GAL7 poly(A)
site were rescued by addition of TAP-purified CPF to ipa1-1
extract (Fig. 1C).
The ipa1-1 mutant bears four point mutations (I109M,
K121I, G226E, and D270V). These mutations result in a loss
of Ipa1 protein (Fig. 1A), and the I109M and K121I mutations
are in a region identified as interacting with Ysh1 by cross-
linking mass-spectrometry [40]. The mutant is slow growing
compared to wild-type cells at 30°C, and this growth defect is
worsened at 37°C (Fig. 1D, left panel). Our previous report
had found that the termination defect and the decrease in the
amount of Pta1 recruited to the 3ʹ end of a transcribed gene
in vivo in the ipa1-1 mutant can be abrogated by Ysh1 over-
expression [41]. Consistent with this result, supplementing
the ipa1-1 mutant with additional copies of the YSH1 gene
on a low copy plasmid was able to rescue the growth defect
observed in ipa1-1 (Fig. 1D, right panel). These results indi-
cate that the growth defect conferred by ipa1-1 is in large part
due to the low level of Ysh1.
mRNA expression changes in ipa1-1 support a processing
defect due to Ysh1 and Ipa1 deficiency
We next tested whether the ipa1-1 mutation altered the effi-
ciency of 3ʹ-end processing in vivo by looking at the level of
endogenous transcripts that contain sequence upstream and
downstream of the poly(A) sites of PDC1 and RPP1B, which
are genes with single poly(A) sites. These transcripts represent
RNA that has not been processed and can be detected by RT-
qPCR with a primer pair that spans the poly(A) site. In
agreement with the defect caused by ipa1-1 in the in vitro
cleavage/polyadenylation reaction, mutation of IPA1 greatly
increased the amount of unprocessed pre-mRNA at the PDC1
and RPP1B poly(A) sites in vivo (Fig. 2A). Overexpression of
YSH1 restored much of the processing at these poly(A) sites,
indicating that the depletion of Ysh1 is a major contributor to
the ipa1-1 3ʹ end processing defect.
To further explore the link between the ipa1-1 mutation
and a defect in mRNA 3ʹ end processing, we examined the
RNA-seq data sets of Costanzo et al. [39] to determine
changes in the mRNA expression profiles of the ipa1-1
mutant compared to that of two mutants with strong
mRNA 3ʹ end processing defects, cft2-1 and pcf11-2 [39].
Cft2 directly contacts Ysh1 in the CPF complex [40], an
interaction conserved with the mammalian homologs,
CPSF100 and CPSF73 [48], and Pcf11 is a subunit of
a different factor, CF IA. For the genes with increased
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Figure 1. The ipa1-1 mutant negatively affects CPF stoichiometry, cell growth and mRNA 3ʹ end processing in vitro.
(A) Expression of subunits of the C/P complex in IPA1 and ipa1-1 cells. Cells expressing Myc13 tagged Ipa1 were grown at 30°C and shifted to 37°C for 1 hour. Cell
extracts were analysed by Western blotting using antibodies against the Myc epitope, C/P subunits, Syc1 (an APT-specific subunit) [43] and actin as a loading control.
The Ysh1 subunit (arrow) is decreased in ipa1-1 cells, and Rna14, Clp1, Cft1 and Swd2 are increased in level (asterisks). (B) Interaction of C/P subunits with the poly(A)
polymerase Pap1. Co-immunoprecipitation was performed with Pap1 antibody and extract from IPA1 or ipa1-1 cells. The eluates were analysed by Western blotting
with antibodies against C/P subunits. Pull-down from IPA1 extract using protein A beads without Pap1 antibody is shown in the left column. (C) Cleavage and poly(A)
addition activities are rescued by addition of purified CPF to ipa1-1 extract. Processing extracts were prepared from IPA1 and ipa1-1 cells grown at 30°C and then
shifted to 37°C for 1 hour. For poly(A) addition, extracts were incubated with ATP and P32-labelled RNA that ends at the GAL7 poly(A) site. For cleavage-only assays,
extracts were incubated with 3ʹ-dATP (a polyadenylation terminator) and P32-labelled RNA containing sequence upstream and downstream of the GAL7 poly(A) site.
RNA products were resolved on a denaturing polyacrylamide gel and visualized with a phosphorimager. Positions of substrate and products are indicated on the
right (open rectangles indicate sequence upstream of the cleavage site, the filled rectangle is sequence downstream, and the open rectangle labelled AAA is
polyadenylated product). The lane marked ‘precursor’ indicates the unreacted substrate. (D) Relative growth of IPA1 (wild-type) and ipa1-1 strains at 30°C and 37°C.
For the left panel, cells were grown in liquid YPD, 10-fold serially diluted, spotted onto YPD plates, and incubated for 3 days at the indicated temperatures. For the
right panel, cells were transformed with the pRS315 plasmid with or without the YSH1 gene and spotted on CM-leu plates to maintain selection of the plasmid.
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expression in ipa1-1, 73% were shared with those up in cft2-1
and 43% with pcf11-2 (Fig. 2B). Of the genes in ipa1-1 that are
decreased in expression, 80% are shared with those decreased
in cft2-1 and 45% with pcf11-2. The finding that the majority
of the ipa1-1-sensitive genes are shared with cft2-1 supports
the idea that a major defect in ipa1-1 is loss of CPF function,
and in particular, a defect in the nuclease module of which
Ysh1 and Cft2 are part.
Interestingly, when we analysed the sequencing data of
Costanzo et al. [39], the IPA1 mRNA in the ipa1-1 mutant
Figure 2. mRNA expression changes support a processing defect due to Ysh1 and Ipa1 deficiency in the ipa1-1 mutant.
(A) Determination of the level of unprocessed transcripts from the PDC1 and RPP1B genes, as determined by RT-qPCR using primers on either side of the poly(A) site
(unprocessed) and a primer pair near the 3ʹ end of the ORF (total). (B) The intersection of genes with increased (left panel, log2 fold-change > 0.5, p-value < 0.2) or
decreased (right panel, log2 fold-change < 0.5, p-value < 0.2) expression in each of three mutant strains – ipa1-1 (green), pcf11-2 (orange), and cft2-1 (purple).
Expression data were obtained from Costanzo et al. [39] and processed as described in Pearson et al. [41]. (C) Cumulative polyadenylation distribution (CPD) plots for
the IPA1 and YSH1 genes for wild-type (black) and ipa1-1 (red), averaged from three biological replicates each, with traces for individual replicates in grey or pink. The
CPD plot [5] shows the empirical likelihood of polyadenylation at or before each position in the gene. Orange bars show coding sequence, with plots oriented such
that the direction of transcription is left to right. The inserts show the log2 tag counts corresponding to mRNAs that are polyadenylated in the 3ʹ UTR of IPA1 or YSH1
for wild-type (black) and ipa1-1 (red). The log2 tag counts correspond to reads from the RNA seq data of Costanzo et al. [39], which uses a method that only returns
reads from the sequence immediately upstream of poly(A) sites. The sequencing data of Costanzo et al. [39] were also used to obtain the CPD plots.
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showed significantly increased expression (log2 fold-change
over wild-type of 5.4) and a suppression of poly(A) sites
within the IPA1 open reading frame (Fig. 2C, top panel). In
wild-type cells, ~30% of the IPA1 transcripts end within the
ORF, but in ipa1-1, these are completely suppressed, leading
to more full-length mRNA isoforms. This observation sug-
gests that the mutant cells are using this mechanism to try to
compensate for the loss of the Ipa1 protein (Fig. 1A) and that
Ipa1 auto-regulates its own expression.
Ysh1 is degraded via the ubiquitin-proteasome system in
ipa1-1
We next investigated the reason for the strong reduction in Ysh1
protein in ipa1-1. RNA sequencing analysis of mRNAs in the
ipa1-1mutant and the isogenic wild-type strain showed no change
in YSH1 mRNA level or shifts in poly(A) site usage (Fig. 2C,
bottom panel). Approximately half of the YSH1 transcripts use
a poly(A) site within the coding sequence, but usage of this site
does not change in ipa1-1 (Fig. 2C). We thus considered that the
decrease in Ysh1 protein in ipa1-1 could be attributed to degrada-
tion by the ubiquitin-proteasome system. Inactivating the protea-
some in the ipa1-1 strain by deleting the UMP1 gene, which is
needed for efficient proteasome assembly [49], restored the level
of Ysh1 to one comparable to that observed in wild-type cells (Fig.
3A). This result suggests that Ysh1 in ipa1-1 might be post-
translationallymodified by ubiquitin and targeted for proteasomal
degradation. To test this, extracts from strains expressing Myc-
tagged Ysh1 were prepared using 2% SDS to disrupt protein–
protein interactions, following the protocol described by Laney
and Hochstrasser [50] for analysis of ubiquitinated proteins. High
molecular weight Ysh1 species were observed in the ipa1-1 ump1▵
cells (Fig. 3B). Similar results were observed if extracts were
prepared in 8M urea (Fig. S1A). To further characterize the larger
species, Ysh1 was immunoprecipitated from diluted SDS extracts,
and immunoprecipitates probed with antibody against ubiquitin
or against the Myc epitope on Ysh1 (Fig. 3C). Some of the larger
Ysh1 species were lost during the immunoprecipitation, perhaps
due to the presence of deubiquitinases in the extract. However,
high molecular weight species containing ubiquitin were detected
in the precipitate from ipa1-1 ump1▵ cells expressing Myc-Ysh1,
but not from ipa1-1 ump1▵ cells lacking the Myc tag or from cells
with the unmutated IPA1 gene (Fig. 3C, lower panel), confirming
the accumulation of ubiquitinated Ysh1 when Ipa1 is defective.
Ubiquitination requires the sequential actions of three
proteins: E1, the ubiquitin-activating enzyme; E2, a ubiquitin-
conjugating enzyme; and E3, a ubiquitin ligase [51,52]. Yeast
has only one E1, but multiple E2 and E3 enzymes. To identify
E2 and E3 enzymes responsible for Ysh1 ubiquitination in
ipa1-1, we mutated candidate E2s or E3s in the ipa1-1 strain
and observed Ysh1 protein level. We reasoned that if an
enzyme responsible for Ysh1 ubiquitination in ipa1-1 was
not functional, Ysh1 would not be targeted for degradation
and would remain at a level comparable to that of wild-type.
Mpe1, which is a CPF subunit in the nuclease module, inter-
acts directly with Ysh1 [40] and contains a RING finger-like
domain found in one type of E3 ubiquitin ligases [53]. RBBP6,
the mammalian homolog of Mpe1, has ubiquitin ligase activ-
ity [54,55]. Thus, Mpe1 is a natural candidate for the E3
responsible for Ysh1 ubiquitination. Indeed, when MPE1
was mutated in ipa1-1, Ysh1 protein level was restored to
that seen in wild-type cells (Fig. 3D) and growth of ipa1-1
improved (Fig. 3F), suggesting that this particular E3 is the
primary regulator of Ysh1 levels when Ipa1 is defective.
For a candidate E2 enzyme, we focused on Ubc4 because of
reported genetic interactions linking Ubc4 with Ipa1 and the
C/P machinery. Of the eleven E2 enzymes in S. cerevisiae [56],
only Ubc4 showed a significant positive genetic interaction
with Ipa1 [39], as determined by improved growth when
mutations in both IPA1 and UBC4 are paired in the same
cell. This genetic interaction suggests that Ipa1 action is
antagonistic to that of Ubc4. In addition, we had earlier
found that the growth defect of the mpe1-C182G,C185G
mutant was suppressed by overexpression of HEL2, encoding
a Ring Finger ubiquitin ligase that physically interacts with
Ubc4 [34,57,58]. Consistent with these interactions, mutation
of UBC4 restored Ysh1 protein level to a normal level in ipa1-
1 (Fig. 3E) and improved growth of ipa1-1 (Fig. 3F). Thus,
even though Ipa1 has been shown to physically interact with
other E2 proteins [59], including Ubc1, Ubc5, Ubc7, Ubc8,
Ubc11, Ubc13, and Pex4, the presence of wild-type genes
encoding these enzymes or that of the close Ubc4 paralog,
Ubc5, is not sufficient to cover for loss of Ubc4 in the ipa1-1
mutant.
UBC4 and MPE1 are required for in vitro ubiquitination of
Ysh1
As described above, mutating UBC4 or MPE1 in the ipa1-1
strain restored the Ysh1 level in vivo. However, restoration of
Ysh1 protein level could be caused by indirect effects of these
mutations. Ubc4 functions in various cellular pathways, and
because Mpe1 is involved in 3ʹ-end processing, its mutation
could affect gene expression of relevant factors. Thus, we
developed an in vitro ubiquitination assay to investigate
whether Ubc4 and Mpe1 are directly involved in Ysh1 ubi-
quitination. Extracts were made from either wild type or
mutant cells and incubated with ubiquitin and CPF purified
from yeast expressing 3xHA-TAP-tagged YSH1 in the mpe1-1
mutation, which causes Mpe1 to dissociate from CPF [53].
We were unable to purify Ysh1 alone as we have found that it
is prone to aggregation.
Using anti-HA antibody, we observed the appearance of high
molecular weight Ysh1 species upon addition of recombinant
ubiquitin and CPF (Fig. 4A, lane 3) to wild-type extract. These
species did not appear when ATP was omitted (Fig. 4A, lane 2)
or when methylated ubiquitin (me-ub) was used in the reactions
(Fig. 4A, lane 4), or when a reaction was performed without
adding Ysh1 (Fig. S1E). ATP is required for the addition of
ubiquitin to an active-site cysteine residue on the ubiquitin-
activating enzyme [52], and methylation of the ε-amino group
of lysines blocks ubiquitin from forming polyubiquitin chains
[60]. These results indicate that the larger forms of Ysh1 corre-
sponded to polyubiquitinated Ysh1. When extracts made from
ubc4▵ or mpe1-1 strains were used, the larger species did not
form efficiently (Fig. 4B and 4C, lanes 3). However, when
recombinant Ubc4 or Mpe1 was added to the reactions, the
larger Ysh1 species accumulated, showing that the missing
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factor needed for Ysh1 polyubiquitination in the ubc4▵ or
mpe1-1 extracts was Ubc4 or Mpe1, respectively (Fig. 4B and
4C, lanes 4). Polyubiquitination of Ysh1 was abrogated when
me-ub was used instead of ubiquitin (Fig. 4B and 4C, lanes 5).
A purified in vitro system ubiquitinates Ysh1
The data presented above confirm a requirement of Ubc4 and
Mpe1 for Ysh1 ubiquitination. We next tested whether Ubc4
and Mpe1 were sufficient to direct Ysh1 ubiquitination by
establishing an in vitro ubiquitination assay with purified pro-
teins. His6-tagged Ubc4 and Mpe1 were expressed in E. coli and
purified by Ni-chelating affinity chromatography. CPF contain-
ing Ysh1-HA3 was purified from yeast as described above, and
recombinant Uba1 (the E1 ubiquitin-activating enzyme) was
obtained commercially. When a mixture of Ysh1, Ubc4,
Mpe1, Uba1 and ubiquitin was incubated with ATP, Ysh1 was
ubiquitinated as shown by the appearance of high molecular
Figure 3. Ysh1 is degraded via the ubiquitin-proteasome system in ipa1-1.
(A) In vivo expression of Ysh1 in ipa1-1 and ipa1-1 ump1▵. Cells were grown at 30°C and then shifted to 37°C for 1 hr. Extracts from these cells were analysed by
Western blotting using an antibody against Ysh1 or actin. (B) Cell lysate prepared from the ipa1-1 ump1▵ cells under denaturing conditions shows higher molecular
weight Ysh1 species. Immunoblots were probed with antibody against a Myc tag on Ysh1. (C) Ysh1 is ubiquitinated in vivo in ipa1-1. Ysh1 was immunoprecipitated
from the indicated cell extracts. The immunoprecipitate in lane 1 was obtained from ipa1-1 ump1▵ cells with untagged Ysh1. The immunoprecipitates were analysed
by Western blotting using antibody against Myc to detect Ysh1 or against ubiquitin. To concentrate the Western signal, a high-percentage acrylamide gel was used
for immunoblotting with anti-ubiquitin. (D, E) Expression of Ysh1 in the ipa1-1 mutant or the ipa1-1 mutant which also contained either a deletion of the UBC4 gene
(ubc4▵) or a mutation of the MPE1 gene (mpe1-DAmP) [39], in which the MPE1 3ʹ UTR is disrupted by insertion of the ampicillin gene, which destabilizes the mRNA,
leading to reduced protein expression. Experiments were performed as described in (A). (F) Growth of ipa1-1 relative to ipa1-1 paired with mutation of MPE1 or UBC4.
Cells were grown on YPD plates at 30°C.
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weight species (Fig. 4D, lane 1). When any component was
omitted, or when ubiquitin was substituted with me-ubiquitin,
these species disappeared, indicating that they correspond to
polyubiquitinated Ysh1 (Fig. 4D and Fig. S1F). These data
indicate that Ubc4 as a ubiquitin conjugase and Mpe1 as
a ubiquitin ligase, along with Uba1 and ubiquitin, are sufficient
to mediate Ysh1 ubiquitination.
We also tested whether a Ysh1–Mpe1 complex expressed
and purified from insect cells (Fig. S1C) was a substrate for
ubiquitination in the reconstituted assay. Ysh1 was readily
ubiquitinated when provided in complex with Mpe1, with
the ubiquitinated species reaching a larger size than in the
previous assay (Fig. 4E), indicating that Ysh1 that is only in
complex with Mpe1 is also substrate for ubiquitination.
Our data showing that the Ysh1 level decreased when Ipa1
was depleted (Fig. 1A) suggested that Ipa1 might somehow
block Ysh1 ubiquitination and degradation. However, addition
of recombinant Ipa1 to the in vitro ubiquitination reaction using
cell extract showed no inhibition of ubiquitination in compar-
ison to bovine serum albumin (BSA) added in the same
Figure 4. Ubc4 and Mpe1 are required for in vitro ubiquitination of Ysh1.
(A) In vitro ubiquitination of Ysh1 in cell extract. Extract from wild-type cells was incubated with ubiquitin and CPF purified from yeast expressing 3xHA-TAP-tagged
YSH1. Components of the in vitro reaction were omitted as indicated, and methylated ubiquitin (me-ub) replaced ubiquitin in lane 4. Ysh1 was detected with HA
antibody. (B) Lysate prepared from ubc4Δ cells does not efficiently ubiquitinate Ysh1 unless recombinant Ubc4 is added. Reactions in lanes 1 and 2 use wild-type
extract (UBC4). Reactions were performed as described in Panel A, and Ysh1 was detected with HA antibody. (C) Lysate prepared from mpe1-1 cells does not
efficiently ubiquitinate Ysh1 unless recombinant Mpe1 is added. Reactions were performed as described in Panel A, and Ysh1 was detected with HA antibody. (D) In
vitro ubiquitination assay with purified proteins. The reaction in lane 1 contains E1 (Uba1), Ubc4, Mpe1, ATP, ubiquitin, and CPF containing Ysh1-HA3. For lanes 2–7,
each component is omitted as indicated, or ubiquitin is replaced with methylated ubiquitin (me-ub). Ysh1 was detected with HA antibody. (E) A Ysh1-Mpe1
heterodimer is ubiquitinated in the reconstituted assay. Increasing amounts of the dimer were added as indicated and reactions performed as described in Panel
D. In all of the experiments in this figure, marker positions are shown on the right of each panel.
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amounts (Fig. S1G). This finding suggests that Ipa1 is not acting
directly to prevent Ubc4 and Mpe1 from modifying Ysh1.
Discussion
Regulating mRNA polyadenylation can help a cell achieve
optimal protein production for a given condition or cell
state. Because of this potential, a greater knowledge of the
fundamental regulatory strategies governing polyadenylation
can contribute to understanding of normal cell physiology
and dysregulation in the disease state [1]. One mechanism
to regulate mRNA polyadenylation is to limit the amount of
the core processing machinery, which can contribute to
a general decrease in mRNA synthesis when less synthetic
capacity is needed. This mechanism can also force favouring
of poly(A) sites with better matches to conserved sequence
elements on the precursor mRNA, leading to mRNA isoforms
with different properties. In this study, we show that the
budding yeast protein Ipa1 controls the level of Ysh1, the
essential endonuclease that cuts mRNA precursor at the poly-
(A) site in preparation for polyadenylation and mRNA
nuclear export. Loss of Ipa1 leads to depletion of the Ysh1
protein without affecting YSH1 mRNA level. Other subunits
of the C/P complex are not depleted, indicating selective
targeting of Ysh1. We discuss below possible mechanisms by
which Ipa1 could act to regulate Ysh1 levels.
Our findings show that increasing the copy number of the
YSH1 gene suppressed the temperature-sensitive growth and
the in vivo processing defect of ipa1-1, indicating that these
defects are largely due to loss of Ysh1. The Ysh1 depletion in
ipa1-1 cells is a consequence of ubiquitin-mediated proteaso-
mal degradation that is facilitated by Mpe1, which, like Ysh1,
is an integral subunit of the nuclease module of CPF [40].
Mpe1 possesses a ubiquitin-like domain, a zinc knuckle, and
a RING finger domain [34]. Thus, by sequence, Mpe1 is also
a member of the RING family of ubiquitin ligases [61], and
our results confirm this predicted activity. We have also
identified Ubc4 as a ubiquitin conjugase that participates in
Ysh1 modification. The sequence of Ipa1 indicates that like
Mpe1, it is a ubiquitin ligase, but of the HECT family [41,59].
While Ipa1 possesses homology to the E2 interaction domain
of this group of proteins, it does not have an active site
cysteine [59], suggesting it does not function like
a conventional HECT-type E3, which covalently receives ubi-
quitin from a partner E2 and transfers it to the target protein.
The molecular mechanism by which Ipa1 prevents Ysh1
degradation is not clear. Biochemical fractionation indicates
that while Ipa1 exists in a complex with only the Ysh1 and
Mpe1 subunits of CPF, it is not a component of CPF itself
[39,40,42]. The direct interaction of Ipa1 with Ysh1 [40] and
intracellular presence of the Ipa1/Ysh1/Mpe1 trimer support
a role involving physical contact between the two proteins. It
is possible that Ipa1, through its interaction with the intrinsically
disordered C-terminal domain of Ysh1 [40], protects Ysh1 from
degradation until it is incorporated into CPF. However, addition
of Ipa1 to an in vitro assay did not block Ysh1 ubiquitination,
suggesting Ipa1 is not preventing productive interaction of
a ubiquitin conjugase like Ubc4 with the Mpe1/Ysh1 dimer.
Since Ipa1 is found in both nucleus and cytoplasm [59],
another role for Ipa1 could be as a co-chaperone to help Ysh1
fold correctly during or after translation (Fig. 5). The Hsp70
and Hsp90 chaperones fold substrate proteins, and accessory
proteins called co-chaperones modulate chaperone activity
and deliver client proteins [62,63,64]. Ysh1 physically inter-
acts with Hsp82 [65], a member of the Hsp90 family, and
several other proteins which assist in protein folding were
associated with Ipa1, including Cpr6 and Aha1 (two co-
chaperones of Hsp82), the Cct4, Cct6, and Cct8 subunits of
the cytosolic Chaperonin Containing TCP1 complex, Hsp42
(a member of the small heat shock chaperone family), Ssa3
(one of the yeast HSP70 ATPases), and Ydj1 (an Ssa3 co-
chaperone and Hsp40 family member) [39]. Cells mutated in
both IPA1 and HSC82, encoding a paralog of Hsp82, grow
more poorly than cells defective for only IPA1 or HSC82 [39],
suggesting that the two genes lie in compensatory pathways.
Some co-chaperones direct Hsp70/Hsp90 chaperones to
participate in either protein degradation or folding [62,63].
Co-chaperones with this activity can be RING-type ubiqui-
tin ligases such as CHIP, and this function has been pro-
posed for the Mpe1 human homolog RBBP6 [66]. Thus, it is
Figure 5. Model for the action of Ipa1 in maintaining the level of Ysh1. In the presence of Ipa1, Ysh1 is correctly folded, and the Ysh1/Mpe1 complex can be
incorporated into CPF, leading to efficient mRNA 3ʹ end processing. In the absence of Ipa1, Ysh1 would not fold properly, leading to ubiquitination and destruction of
Ysh1, inefficient mRNA 3ʹ end processing, and alterations in the choice of the cleavage site.
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possible that Ipa1 acts by recruiting a chaperone complex to
Ysh1 or otherwise promoting the folding activity of the
chaperones. Once folded, the Ysh1/Mpe1 complex could
be incorporated into CPF (Fig. 5), through a switch in
which Ipa1 interacting at the Ysh1 C-terminal domain is
replaced with the CPF Cft2 subunit [40]. In the absence of
Ipa1, Ysh1 would not fold properly, leading to ubiquitina-
tion and destruction of Ysh1, inefficient mRNA 3ʹ end
processing, and as we described previously, alterations in
the choice of poly(A) site position [41]. Our model for Ipa1
action predicts that the Ipa1/Ysh1/Mpe1 complex might be
exquisitely tuned for folding or instead, rapid degradation of
Ysh1, depending on the needs of the cell. However, we
cannot exclude other possible models. For example, Ipa1
could recruit or regulate the abundance of
a deubiquitinase that counteracts the activity of Ubc4 and
Mpe1 on Ysh1, although there is no evidence for this from
reported physical interactions. Ubiquitination does not
necessarily lead to degradation [67], and Ipa1 could pro-
mote ubiquitination of a factor in a way that regulates its
activity towards Ysh1.
Our study suggests that yeast has evolved an easily tun-
able mechanism that ensures the correct amount of Ysh1
when cells are growing in optimal conditions. It is possible
that this mechanism could also allow rapid removal of Ysh1
and a general down-regulation of the polyadenylation capa-
city of the cell in less favourable growth conditions. Having
to modulate only one subunit of the C/P complex (i.e. Ysh1)
would provide a means to quickly match this aspect of
mRNA synthesis to changing growth conditions.
Interestingly, the Ipa1 homolog, UBE3D/UBE2CBP, physi-
cally interacts in quantitative proteomics screens with
CPSF-73 [68,69], the counterpart of Ysh1. While UBE3D
has been implicated in cell cycle regulation [70], age-related
macular degeneration [71], the inflammatory condition of
aggressive juvenile periodontitis [72], and alterations in the
fatty acid profile of muscle [73], its functional role in mam-
malian cells have not been determined. Future experiments
may not only elucidate the precise mechanism by which
Ipa1 modulates Ysh1 degradation but also explore whether
this regulatory relationship is conserved across eukaryotes.
Materials and methods
Yeast strains and plasmids construction
The S. cerevisiae strains used in this study are given in Table 1.
SDL98, SDL99, SDL107, and SDL116 were constructed by
inserting a Myc13 tag at the C terminus of the endogenous
YSH1 gene as described [74].
For Ysh1 purification in yeast, theYSH1-3xHA-TAP
(SDL184) strain was constructed using mpe1-1 (W303a;
ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 mpe1-1)
[53], as the host (described below). SDL110 (W303a; ade2-1
ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100)
For pRS315-YSH1, the YSH1 is under the control of theMPE1
promoter and terminator sequences. The coding sequence of
YSH1 was amplified from genomic DNA by PCR using the
upstream primer NdeI-BRR5-fwd (5ʹ -CTCTACATATG
GAGCGAACAAATACAACAACATTC-3ʹ) and the downstream
primer NotI-BRR5-rev (5ʹ-tacagGCGGCCGCTTAACATAGC
GGTGTGACCAAATTACC-3ʹ). The PCR product was digested
with NdeI andNotI and was cloned into the pRS315-MPE1 vector
[34], which was digested with the same restriction enzymes.
pET21b-MPE1 construction was described in Lee and
Moore [34]. For pTD68-Flag-UBC4 construction, DNA
sequence containing BamHI-Flag-UBC4-XhoI was ordered
as gBlocks from IDT (sequence shown below), digested with
BamHI and XhoI, and cloned into pTD68 digested with the
same restriction enzymes. The construction of pTD68 was
described in Uehara et al. [75]. The UBC4 sequence (under-















For pTD68-V5-IPA1 construction, the same scheme was
used as described for pTD68-Flag-UBC4. The DNA sequence
containing BamHI-V5-IPA1-XhoI was ordered as gBlocks
from IDT (sequence shown below). The IPA1 sequence









Table 1. Yeast strains used in this study.
Strain Genotype
W303a ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100
BY4741a his3Δ1 leu2Δ0 ura3Δ0 met15Δ0
SDL164 As BY4741a but ipa1-1::KanR [39]
SDL101 As BY4741a but ipa1-1::KanR, ump1Δ::LEU2 (This study)
SDL89 As BY4741a but ipa1-1::KanR,ubc4Δ::natR [39]
SDL90 As BY4741a but ipa1-1::KanR,mpe1-DAmP::natR [39]
SDL106 As BY4741a but ipa1-1::KanR,ubc7Δ::LEU2 [39]
SDL98 As BY4741a but YSH1-Myc13::HisMX6 (This study)
SDL99 As BY4741a but ipa1-1::KanR,YSH1-Myc13::HisMX6 (This study)
SDL107 As BY4741a but ump1Δ::LEU2,YSH1-Myc13::HisMX6 (This study)
SDL116 As BY4741a but ipa1-1::KanR, ump1Δ::LEU2, YSH1-Myc13::HisMX6
(This study)
SDL57 BY4742a; his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 ubc4Δ::LEU2(This study)
SDL110 As W303a but IPA1-Myc13::HisMX6 (This study)
SDL103 As BY4741a but IPA1-Myc13::HisMX6 (This study)
SDL104 As BY4741a but ipa1-1-Myc13::HisMX6 (This study)


























The YSH1-3xHA-TAP in mpe1-1 background was gener-
ated by inserting the 3xHA-TAP sequence immediately
upstream of the stop codon of YSH1 as previously described
with some modifications [76]. In brief, 3xHA-TAP-TRP1
bracketed by sequences flanking the YSH1 stop codon was
amplified by PCR with pBS1479 as a template by using Q5










TTTtacgactcactataggg-3ʹ). Each primer has a pBS1479 specific
sequence (underlined) and a 50-base (fwd primer) and 100-
base (reverse primer) YSH1-specific sequence. mpe1-1 cells
were transformed with the YSH1-3xHA-TAP-TRP1 PCR pro-
duct, followed by selection for the TRP1 marker.
Transformants harbouring YSH1-3xHA-TAP-TRP1 were ver-
ified by PCR and the expression of YSH1-3xHA-TAP was
confirmed by Western blot.
Yeast spot assay and cultures
Growth properties were analysed by growing strains in liquid
yeast extract-peptone-dextrose (YPD) at room temperature to
an optical density at 600 nm (OD600) of 1.0, spotting 5 of 10-
fold serial dilutions onto YPD plates, and incubating the
plates for 3 days at 30°C or 37°C.
Affinity purification of Ysh1-3HA-TAP and PTA1-TAP
Yeast expressing 3xHA-TAP-tagged YSH1 in the mpe1-1
background [53] were grown in 8 L of YPD at 25°C to an
OD600 = 0.7 and shifted to 37°C for 1.5 h. For purification of
CPF, FY23 cells carrying PTA1-TAP [22] were grown in 8
L of YPD at 30°C to an OD600 = 1.0. Extracts were prepared as
described previously [77] except omitting the ammonium
sulphate precipitation step. CPF was purified according to
the standard TAP procedure [76] except that the IgG beads
were washed with high salt buffer (1.5 M NaCl) for CPF used
in the in vitro ubiquitination assays. The eluates were sepa-
rated on an SDS-8% polyacrylamide gel and detected by silver
staining (Fig. S1B). Ysh1 was confirmed by Western blot
analysis using anti-HA antibody.
Preparation of extracts and in vitro mRNA 3ʹ end
processing assays
Preparation of yeast processing extracts and processing assays
were done as described previously [77]. For the rescue experi-
ment with TAP-purified CPF, 10–30 ng of CPF was mixed
with yeast extracts and incubated for 5 min at 25°C before
RNA substrate was added. Western blotting to determine
levels of proteins in the processing extracts was performed
according to standard procedures. The monoclonal antibodies
against Pta1 and Pap1 have been described previously [77].
Polyclonal antibodies against Rna14 and Rna15, and Ysh1
were a gift from H. Domdey. Polyclonal antibody against
Mpe1 was a gift from F. Wyers. The antibodies against
Ssu72, Pfs2, Fip1, and Yth1 have been described pre-
viously [5].
Co-immunoprecipitation assays
Yeast processing extracts (1 mg) prepared as described pre-
viously [77] were incubated with anti-Pap1 antibody over-
night at 4°C in 500 μl of buffer IP-150 (10 mM Tris-HCl at
pH 7.9, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM
dithiothreitol [DTT], 1 mM phenylmethylsulfonyl fluoride
[PMSF], 2 μM pepstatin A, 0.6 μM leupeptin, 0.05% NP-40).
IP samples were then incubated with protein G beads for 1 hr
at 4°C, washed 5X with 1 ml of buffer IP-150, and eluted with
70 μl of SDS sample buffer (without reducing reagent) for 15
min at 25°C. The eluates were resuspended with SDS sample
buffer, boiled for 3 min, and analysed in an SDS-10% poly-
acrylamide gel.
In vivo detection of Ysh1 ubiquitination
The method for purifying ubiquitinated proteins under dena-
turing conditions was described previously by Laney and
Hochstrasser [78]. For our experiments, cells were grown in
20 ml of minimal medium at 30°C to an OD600 = 0.5 and
shifted to 37°C for 1 hour. Cells were resuspended in 200 μl
SDS buffer (2% SDS and 45 mM HEPES, pH 7.5), boiled for
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15 min, and centrifuged at 14,000 x g for 5 min. The super-
natant was diluted with 4 ml ice-cold Triton lysis buffer (1%
Triton X-100, 150 mM NaCl, 50 mM HEPES, pH 7.5, 5 mM
EDTA, 20 mM NEM, 1 mM 1,10-phenanthroline monohy-
drate, 1 mM PMSF, 2 μM pepstatin A, and 0.6 μM leupeptin)
and incubated with anti-Myc antibody for 30 min at 4°
C. Protein G beads (Santa Cruz) were then added and rotated
for another 30 min. Beads were washed three times with 1 ml
Triton lysis buffer containing 0.05% SDS, resuspended in SDS
sample buffer, boiled for 5 min, and analysed in an SDS-
PAGE. Western blotting was performed according to standard
procedures except that after transfer, the nitrocellulose mem-
brane was submerged in water and autoclaved for 40 min to
improve immuno-detection of ubiquitin, blocked with 5%
bovine serum albumin, and then probed with anti-ubiquitin
from Santa Cruz (sc-8017). For detection of Ysh1, anti-Myc
antibody (9E10) was used.
Recombinant protein expression and purification
Mpe1 was expressed and purified from E. coli Rosetta (DE3)
cells according to Lee and Moore [34]. Recombinant Ubc4
and Ipa1 were expressed and purified from E. coli Rosetta cells
as in Cho et al. [79] with the following exceptions. Buffer
A was composed of 50 mM sodium phosphate buffer, pH 8.0,
300 mM NaCl, 10 mM Imidazole, 5% glycerol, 5 mM β-
mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride
[PMSF], 2 μM pepstatin A, and 0.6 μM leupeptin. Buffer
B was composed of 50 mM sodium phosphate buffer, pH
8.0, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 2 μM pepstatin A, and 0.6 μM leupeptin. Ipa1-His6
was expressed from a pET21a plasmid, and protein purified
by nickel affinity chromatography. Ubc4 was expressed from
the pTD68 plasmid [75], which adds a His6-SUMO-FLAG tag
to the N-terminus of Ubc4, and purified as described in
Uehara, et al. [75]. After purification of the Ubc4 fusion
protein by nickel-affinity chromatography, the His6-SUMO
tag was released using His6-tagged SUMO protease. Cleavage
reactions were passed through Ni-NTA resin to remove free
H-SUMO and the protease. The purified proteins (Fig. S1D)
were dialysed against buffer D (50 mM Tris, pH 7.9, 150 mM
NaCl, 0.5 mM DTT, 20% glycerol, 1 mM phenylmethylsulfo-
nyl fluoride (PMSF), 2 μM pepstatin A, and 0.6 μM
leupeptin).
For expression of the Ysh1–Mpe1 complex in Sf9 insect
cells, we used Bac-to-Bac technology (Thermo Fisher) as
described by Cooper et al. [80]. The Mpe1 ORF tagged with
Myc (5ʹ) and His6 (3ʹ) was inserted into pFastBac-Dual after
the pPolh promoter using the SacI and NotI sites, and the
Ysh1 ORF tagged with His6 (5ʹ) and 3HA (3ʹ) was inserted
into pFastBac-Dual after the p10 promoter using the XhoI
and NheI sites. The pFASTbac-Dual-Ysh1-Mpe1 recombinant
plasmid was validated by Sanger sequencing. The construct
was transformed into DH10Bac cells and positive colonies
were selected by Bluo-Gal. Bacmid DNA was prepared by
using the P1, P2 and N3 buffer from Qiagen miniprep kit
(Cat. No. 27106) followed by isopropanol precipitation. The
purified bacmid DNA was used for transfection in Sf9 insect
cell to make baculovirus.
For expression and purification of the Ysh1–Mpe1 com-
plex, Sf9 cells were grown in Sf900-SFM medium (Thermo
Fisher) to a density of 2 × 106 cells/ml and infected with
recombinant baculovirus by adding 7.5 ml of the viral stock
from the third passage (P3) to 1.5 litres of cells in a 5-litre
incubation bottle. Seventy-two hours after infection, cells were
harvested and resuspended in solubilization buffer (50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 10 mM imidazole, 10%
glycerol, 10 uM pepstatin A, 100 uM leupeptin and 1mM
PMSF). The suspension was lysed by passing it three times
through an M-110S microfluidizer according to the manufac-
turer’s instructions. Supernatant was collected from lysate by
centrifugation at 4,000 g for 25 min. Ysh1 and Mpe1 in 45 mL
of supernatant were isolated by adding 1 mL Ni Superflow
resin (GE Healthcare). After incubation for 1 h, the resin was
washed three times with 15 column volumes of 50 mM Tris
pH 8.0, 150 mM NaCl and 10mM imidazole. Ysh1 and Mpe1
were eluted with 50 mM Tris pH 8.0, 150 mM NaCl, and 300
mM imidazole and concentrated in a centrifuge filter (mole-
cular weight cut-off of 30 kDa, Millipore EMD). Ysh1–Mpe1
complex was further purified by anti-HA beads (Thermo
Fisher, #26181) according to the manufacture instructions
and analysed by coomassie blue staining and Western Blot
using anti-HA antibody (sc-7392) and Anti-MYC antibody
(sc-40) from Santa Cruz (Fig. S1C). The concentrations of
purified proteins were determined by BCA protein assay
(Thermo Fisher).
In vitro ubiquitination assays
Yeast crude extracts were prepared as described in Zhao et al.
[77]. The extracts are diluted to 1 μg/μl in buffer D (50 mM
Tris, pH 7.9, 150 mM NaCl, 0.5 mM DTT, 20% glycerol, 1
mM phenylmethylsulfonyl fluoride [PMSF], 2 μM pepstatin
A, and 0.6 μM leupeptin). The reaction includes 2 μg of
extract, 2 μl of 5X reaction buffer (100 mM Tris pH 7.5, 100
mM MgCl2, 10 mM ATP, and 5 mM DTT), 15 μM ubiquitin
aldehyde (Boston Biochem U-201), 0.2 mM ubiquitin (Boston
Biochem U-100sc) or 0.2 mM me-ubiquitin (Boston Biochem
U-501), and the CPF-high-salt fraction in a final volume of 10
μl. For recombinant Ubc4 and Mpe1 add-back experiments,
protein was added to 1.5 μM in a final volume of 10 μl. These
reactions were carried out at 37°C for 10 min. The reactions
with purified components shown in Fig. 3D include 10 nM
Uba1 (Boston Biochem E-300), 200 nM Ubc4, 200 nM Mpe1,
0.2 mM ubiquitin or 0.2 mM me-ubiquitin and ~200 nM
Ysh1-high-salt fraction and 2 μl of 5X reaction buffer (same
as above) in a final volume of 10 μl. These reactions were
carried out at 30°C for 20 min. The in vitro ubiquitination
assays (total reaction volume of 20 μL) shown in Fig. 3E were
performed using Uba1 (125 nM), Ubc4 (500 nM), 1 μg/μL
ubiquitin, the Ysh1–Mpe1 complex expressed in insect cells at
the indicated concentrations in 100 mM Tris, pH 7.5, 100 mM
MgCl2, 10 mM ATP, 4 mM MgCl2, and 5 mM DTT for 30
min at 30°C. Reactions were stopped by addition of SDS
sample buffer containing 4% β-mercaptoethanol, heated at
95°C for 5 min, and resolved on 10% Bis-Tris gels or by SDS-




Total RNA from wild-type or mutant cells was isolated using
the Hot Phenol Method [81] and Heavy Phase Lock Gel tubes
(Quantabio), and treated with RQ1 DNase (Promega). DNA-
free RNA was subjected to reverse transcription using random
hexamers. The resulting cDNA samples were analysed using
real-time PCR analysis performed in a 12 µl reaction with 0.5
µl of 10 µM forward and reverse primers, 5 µl of SYBR Green
Supermix (BIO-RAD), 1 µl cDNA, and 5 µl of distilled water.
The primer sequences are listed in Table 2. The expression of
the unprocessed transcript of a given gene was normalized to
the expression of total mRNA of that gene.
Global gene expression analysis
RNA sequencing data sets for the ipa1-1, pcf11-2 and cft2-1 were
obtained from Costanzo et al. [39] and processed and analysed
as described previously for the ipa1-1 data set [41]. Differential
expression assessment was made with DESeq2 [80], using
a threshold of log2 fold-change > 0.5, p-value < 0.2 for increased
genes, or log2 fold-change < 0.5, p-value < 0.2 for decreased
genes, and based only upon poly(A) site tags that supported
a full-length mRNA transcript. Venn diagrams were generated
with eulerr [50]. Cumulative polyadenylation distribution
(CPD) plots were determined as described in Graber et al. [5].
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